MUWRP/AVAC: Biomedical HIV Prevention Research Stakeholder Training Resource

This manual, developed by 2010 AVAC Advocacy Fellow Jauhara Nanyondo, is an HIV prevention literacy tool intended to improve reporting by Ugandan media. It covers background information on HIV, provides an overview of existing and emerging prevention options, and discusses clinical research process and ethics.

Good Participatory Practice: Guidelines for biomedical HIV prevention trials second edition (Thai)

The Good Participatory Practice (GPP) guidelines offer trial funders, sponsors and implementers systematic guidance on how to engage stakeholders throughout the research lifecycle of HIV Prevention Trials.

This second edition of the guidelines, published in 2011, contains three sections: The Importance of Good Participatory Practice, Guiding Principles of GPP in Biomedical HIV Prevention Trials and Good Participatory Practices in Biomedical HIV Prevention Trials. The sections provide context, foundational principles and key practices.

Good Participatory Practice: Guidelines for biomedical HIV prevention trials second edition (Russian)

The Good Participatory Practice (GPP) guidelines offer trial funders, sponsors and implementers systematic guidance on how to engage stakeholders throughout the research lifecycle of HIV Prevention Trials.

This second edition of the guidelines, published in 2011, contains three sections: The Importance of Good Participatory Practice, Guiding Principles of GPP in Biomedical HIV Prevention Trials and Good Participatory Practices in Biomedical HIV Prevention Trials. The sections provide context, foundational principles and key practices.

Good Participatory Practice: Guidelines for biomedical HIV prevention trials second edition (Portuguese)

The Good Participatory Practice (GPP) guidelines offer trial funders, sponsors and implementers systematic guidance on how to engage stakeholders throughout the research lifecycle of HIV Prevention Trials.

This second edition of the guidelines, published in 2011, contains three sections: The Importance of Good Participatory Practice, Guiding Principles of GPP in Biomedical HIV Prevention Trials and Good Participatory Practices in Biomedical HIV Prevention Trials. The sections provide context, foundational principles and key practices.

Letter to Ambassador Goosby from Kenyan Civil Society

This letter on behalf of civil society organizations working in HIV and AIDS in Kenya offers recommendations for PEPFAR’s Kenya Country Operational Plan (COP) in 2013. The letter includes calls for increased investment in HIV treatment options and enhanced participation of CSO-selected civil society groups in every stage of the COP drafting process.

Community Stakeholder Checklist

The Community Stakeholder Checklist is a set of questions that can be used by community stakeholders to evaluate a research team’s compliance with the Good Participatory Practice guidelines. The checklist can be used as a starting point for dialogue with a research team, a way to share experiences with other stakeholders or as an assessment tool.

2005 AVAC Report: AIDS Vaccines at the Crossroads

This year’s Report offers recommendations for the field in general, the Global HIV Vaccine Enterprise, policy makers, researchers and communities. Some of these recommendations will be familiar because AVAC has made them before, and they are reiterated because it is AVAC’s belief that they are still needed. The Report also provides an update on tenofovir pre-exposure prophylaxis research.

2004 AVAC Report: AIDS Vaccine Trials: Getting the Global House in Order

This year’s Report focuses on how the field is readying itself for the road ahead. Several chapters address different aspects of “readiness”—a term that means different things to different people, but that is at the heart of the AIDS vaccine advocacy agenda today.

2013 AVAC Report: Research and Reality

Research & Reality calls on funders and researchers to capitalize on lessons learned from a range of recent HIV prevention trials via better problem solving, more critical thinking and coordinated action. This year’s AVAC Report identifies progress and gaps in large-scale human trials, rollout of proven options and ongoing research for new advances that women and men will want to use.

Good Participatory Practice: Guidelines for biomedical HIV prevention trials, second edition

The Good Participatory Practice (GPP) guidelines offer trial funders, sponsors and implementers systematic guidance on how to engage stakeholders throughout the research lifecycle of HIV prevention trials.

This second edition of the guidelines, published in 2011, contains three sections: The Importance of Good Participatory Practice, Guiding Principles of GPP in Biomedical HIV Prevention Trials and Good Participatory Practices in Biomedical HIV Prevention Trials. The sections provide context, foundational principles and key practices.